TUESDAY, SEPTEMBER 27, 2016

GSK announces partnership with Save the Children to save one million children

GlaxoSmithKline, a research-based pharmaceutical company, announced a partnership on Thursday with the U.K.-based organization Save the Children to accelerate the availability of children's medicines in Sub-Saharan Africa.

The two organizations will work together by sharing expertise, reach, resources and influence to battle some of the major causes of childhood death. Among the key initiatives of the collaboration are the transformation of an antiseptic used in mouthwash into a life-saving product for newborns and the roll-out of a powdered antibiotic in child-friendly doses to battle pneumonia.

"A partnership of this scale gives us an opportunity to do something amazing - to save the lives of one million children and to transform the lives of millions more," Sir Andrew Witty, the CEO of GSK, said. "At GSK we are motivated by developing innovative life-saving medicines and getting them to the people that need them. By joining forces with Save the Children, we can amplify these efforts to create a new momentum for change and stop children dying from preventable diseases. I hope this partnership inspires GSK employees and sets a new standard for how companies and NGOs can work together towards a shared goal."

For the first time, Save the Children will help GSK to research and develop medicines for children to accelerate progress on innovative life-saving interventions for children under the age of five. GSK will use Save the Children's health expertise and on-the-ground experience to reach children in marginalized and remote communities.

"This ground breaking partnership involves both organizations working in genuinely new ways to save the lives of a million children," Justin Forsyth, the chief executive of Save the Children, said. "In the past Save the Children may not have embarked on a collaboration with a pharmaceutical company like GSK. But we believe we can make huge gains for children if we harness the power of GSK's innovation, research and global reach."

The partnership will also focus on widening vaccine coverage to the poorest children in the world. GSK and Save the Children aim to save the lives of one million children in the next five years.

Flagship programs will start in Kenya and the Democratic Republic of Congo. The experience in the flagship programs will inform programs in other countries in Sub-Saharan Africa, Latin America and Asia.